Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

https://pubmed.ncbi.nlm.nih.gov/33020647/

Authors: Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA et al.

Nat Med 2020;26(10):1569-1575.